Breast Cancer: Multiple Subtypes within a Tumor?

Yeo, Syn Kok; Guan, Jun‐Lin

doi:10.1016/j.trecan.2017.09.001

Cited by 310 publications

(242 citation statements)

References 69 publications

Supporting

Mentioning

213

Contrasting

Unclassified

Order By: Relevance

“…Changes in the compositions of lipid isomers are indicators of altered stearoyl-CoA desaturase (SCD) or phospholipase activities 59 . Existing studies have shown that cancer cells in solid tumors are heterogeneous, which could lead to large variations in lipid compositions of tissues from different patients 64 . Among the total 43 PC structure isomers identified, 29 were sn-isomers and 14 were C=C location isomers.…”

Section: Analysis Of Paired Normal and Cancerous Human Lung Tissuesmentioning

confidence: 99%

Large-scale lipid analysis with C=C location and sn-position isomer resolving power

Cao¹,

Cheng²,

Yang³

et al. 2020

Nat Commun

144

183

View full text Add to dashboard Cite

Lipids play a pivotal role in biological processes and lipid analysis by mass spectrometry (MS) has significantly advanced lipidomic studies. While the structure specificity of lipid analysis proves to be critical for studying the biological functions of lipids, current mainstream methods for large-scale lipid analysis can only identify the lipid classes and fatty acyl chains, leaving the C=C location and sn-position unidentified. In this study, combining photochemistry and tandem MS we develop a simple but effective workflow to enable large-scale and near-complete lipid structure characterization with a powerful capability of identifying C=C location(s) and sn-position(s) simultaneously. Quantitation of lipid structure isomers at multiple levels of specificity is achieved and different subtypes of human breast cancer cells are successfully discriminated. Remarkably, human lung cancer tissues can only be distinguished from adjacent normal tissues using quantitative results of both lipid C=C location and sn-position isomers.

show abstract

Section: Analysis Of Paired Normal and Cancerous Human Lung Tissuesmentioning

confidence: 99%

Large-scale lipid analysis with C=C location and sn-position isomer resolving power

Cao¹,

Cheng²,

Yang³

et al. 2020

Nat Commun

144

183

View full text Add to dashboard Cite

show abstract

“…Breast cancer is the second major cause of death in women, and its heterogeneous molecular nature is a significant obstacle in treatment planning [65]. It has several subtypes, such as human epidermal growth factor receptor 2 (HER2), triple-negative or basal-like, Luminal A and Luminal B type depending on the presence or absence of several hormone receptors like HER2, estrogen, and progesterone [66][67][68]. Recently, another subtype of breast cancer known as the claudin-low subtype has been reported [67].…”

Section: Claudin-1 and Breast Cancermentioning

confidence: 99%

Claudin-1, A Double-Edged Sword in Cancer

Bhat

Syed

Therachiyil

et al. 2020

IJMS

102

View full text Add to dashboard Cite

Claudins, a group of membrane proteins involved in the formation of tight junctions, are mainly found in endothelial or epithelial cells. These proteins have attracted much attention in recent years and have been implicated and studied in a multitude of diseases. Claudins not only regulate paracellular transepithelial/transendothelial transport but are also critical for cell growth and differentiation. Not only tissue-specific but the differential expression in malignant tumors is also the focus of claudin-related research. In addition to up- or down-regulation, claudin proteins also undergo delocalization, which plays a vital role in tumor invasion and aggressiveness. Claudin (CLDN)-1 is the most-studied claudin in cancers and to date, its role as either a tumor promoter or suppressor (or both) is not established. In some cancers, lower expression of CLDN-1 is shown to be associated with cancer progression and invasion, while in others, loss of CLDN-1 improves the patient survival. Another topic of discussion regarding the significance of CLDN-1 is its localization (nuclear or cytoplasmic vs perijunctional) in diseased states. This article reviews the evidence regarding CLDN-1 in cancers either as a tumor promoter or suppressor from the literature and we also review the literature regarding the pattern of CLDN-1 distribution in different cancers, focusing on whether this localization is associated with tumor aggressiveness. Furthermore, we utilized expression data from The Cancer Genome Atlas (TCGA) to investigate the association between CLDN-1 expression and overall survival (OS) in different cancer types. We also used TCGA data to compare CLDN-1 expression in normal and tumor tissues. Additionally, a pathway interaction analysis was performed to investigate the interaction of CLDN-1 with other proteins and as a future therapeutic target.

show abstract

“…It is therefore needed to elicit a better response with treatment strategies in patients. 2 According to the profiling of gene expression, breast cancer has been classified into four types: luminal A, luminal B, basal-like breast cancer and HER-2 overexpressed breast cancer. Luminal A being the most common type consists of ER and/or PR positive, HER-2 negative and Ki-67 expression less than 14%.…”

Section: Introductionmentioning

confidence: 99%

Small Molecules Polypharmacology for the Treatment of Breast Cancer: A Roadmap for the Future Chemotherapy

Acharya¹,

Pattanayak²

2020

IJPER

View full text Add to dashboard Cite

Background: Breast cancer is considered as the most common ailment in women across the globe. There are a variety of major factors for the growth and progression of breast cancer. Although genetic changes are key factors for cancer progression, epigenetic and environmental factors also have their fair share of contribution. Hypothesis: An attempt has been made in the review to highlight about small molecule polypharmacology for the treatment of breast cancer which is the design of small molecules (molecular weight <900Da) that aim for two or more cancer targets (tyrosine kinases). Small molecules are advantageous over conventional chemotherapy with higher target specificity, lesser known side effects, simplified dosing schedule, non-invasive dosing and improved patient compliance. Results and Conclusion: Small molecules have been introduced since the past two decades and has been a potential success in the field of cancer chemotherapy, but there are lot more to explore. The review mainly focuses on the essential cellular signaling pathways involved in breast cancer progression and the recent small molecule inhibitors that show promising activity against the pathways.Reetuparna Acharya is a Research Scholar from Birla Institute of Technology, Mesra, Ranchi and she is currently pursuing her Ph.D. on small molecules synthesis and evaluation of their molecular mechanistic pathway on mammary carcinogenesis. She had finished her Master's degree in Pharmacology with the molecular evaluation of the anticancer mechanism of quinazoline derivatives on breast cancer model in Sprague Dawley rats.

show abstract

Breast Cancer: Multiple Subtypes within a Tumor?

Cited by 310 publications

References 69 publications

Large-scale lipid analysis with C=C location and sn-position isomer resolving power

Large-scale lipid analysis with C=C location and sn-position isomer resolving power

Claudin-1, A Double-Edged Sword in Cancer

Small Molecules Polypharmacology for the Treatment of Breast Cancer: A Roadmap for the Future Chemotherapy

Contact Info

Product

Resources

About